How to improve healthcare in times of crises
Collaboration is needed to advocate for resilient healthcare systems that can navigate crises and deliver high-quality care to patients with cancer, even in the most trying circumstances
Performance data from AI tools show progress in oncology
Cancer imaging and identification of predictive biomarkers are the best performed tasks reported in studies presented at ESMO Congress 2023
The future of real-world research is now
ESMO is at the forefront of digital oncology, with some initiatives that support oncologists navigating the emerging opportunities in the field of real-world data research
When your patient is the global population
Dr Raffaella Casolino is the third ESMO young medical oncologist serving as a cancer expert on the WHO Cancer Control team
“Green” prescribing may limit the environmental impact of oncology
Tools and targeted communication are needed to guide clinical practice and help healthcare professionals make sustainable choices
Does AI hold the future of early cancer detection?
Technology promises to improve understanding of cancer risk and lesion biology, but clear regulation is urged to implement innovation in cancer screening programmes
Access to high-quality care for sarcomas is still unequal worldwide
Delays and poor patient journey are reported in resource-constrained countries, while awareness campaigns and healthcare service reorganisation have improved rare cancer management in more developed areas
Ukraine: what help for refugees with breast cancer?
In neighbouring countries, oncologists are seeing a growing number of female refugees with breast cancer whose treatment may have started before they left Ukraine and urgently needs to be continued for good outcomes to be achieved.
Cancer care in war zones: what have we learnt?
In recent conflicts, good response to the health needs of refugees with cancer in receiving countries is consequence of an analysis of local cancer centres capacity and special measures to avoid fragmented care
Anti-cancer medicines are typically approved in the USA eight months before Europe
Discrepancies in anti-cancer drug approvals around the globe are even bigger in low- and middle-income countries, raising some questions about how they impact on patients’ access to quality cancer care.